In the future, the partial agonist of PPARγ (such as telmisartan, mesalazine, etc.)might be added to the treatment of clinical diabetes as a protective agent to reduce the risk of neurological complications in patients with diabetes. Here, PPARG is linked to diabetes mellitus.